SAN DIEGO, March 29, 2026 (GLOBE NEWSWIRE) — The regulation company of Robbins Geller Rudman & Dowd LLP declares clients or acquirers of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) not unusual inventory between August 3, 2023 and December 26, 2025, each dates inclusive (the “Class Period”), have till Monday, April 6, 2026 to hunt appointment as lead plaintiff of the Ultragenyx category motion lawsuit. Captioned Bailey v. Ultragenyx Pharmaceutical Inc., No. 26-cv-01097 (N.D. Cal.), the Ultragenyx category motion lawsuit fees Ultragenyx in addition to sure of Ultragenyx’ executives with violations of the Securities Trade Act of 1934.
In the event you suffered considerable losses and need to function lead plaintiff of the Ultragenyx category motion lawsuit, please supply your knowledge right here:
https://www.rgrdlaw.com/cases-ultragenyx-pharmaceutical-inc-class-action-lawsuit-rare.html
CASE ALLEGATIONS: Ultragenyx is a biopharmaceutical corporate that specializes in the id, acquisition, construction, and commercialization of novel merchandise for the remedy of infrequent and ultra-rare genetic sicknesses.
The Ultragenyx category motion lawsuit alleges that defendants all the way through the Magnificence Length made false and/or deceptive statements and/or didn’t reveal that: (i) defendants created the misconception that they possessed dependable knowledge referring to the consequences of setrusumab on sufferers with variable kinds of Osteogenesis Imperfecta (“OI”), whilst additionally minimizing chance that sufferers in Ultragenyx’ Segment III Orbit find out about would fail to reach a statistically important aid in annualized fracture charge (“AFR”), such that the second one intervening time research may well be carried out and offered to the making an investment public; and (ii) actually, Ultragenyx’ optimism within the Segment III Orbit find out about’s effects and intervening time research benchmark had been out of place as a result of Ultragenyx didn’t put across the danger related to basing such threshold figures on Segment II effects that had no placebo keep watch over staff for suitable comparability and thus had now not dominated out that the aid in AFR from that find out about may simply be brought about by way of an greater usual of care and the placebo impact of being supplied a unique remedy.
THE LEAD PLAINTIFF PROCESS: The Personal Securities Litigation Reform Act of 1995 lets in any investor who bought or obtained Ultragenyx not unusual inventory throughout the Magnificence Length to hunt appointment as lead plaintiff within the Ultragenyx category motion lawsuit. A lead plaintiff is in most cases the movant with the best monetary hobby within the aid sought by way of the putative category who may be standard and ok of the putative category. A lead plaintiff acts on behalf of all different category participants in directing the Ultragenyx investor category motion lawsuit. The lead plaintiff can make a selection a regulation company of its option to litigate the Ultragenyx shareholder category motion lawsuit. An investor’s talent to proportion in any attainable long run restoration isn’t dependent upon serving as lead plaintiff of the Ultragenyx category motion lawsuit.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is among the global’s main advanced category motion corporations representing plaintiffs in securities fraud and shareholder rights litigation. Our Company ranked #1 on the latest ISS Securities Magnificence Motion Products and services Most sensible 50 Record, getting better greater than $916 million for traders in 2025. This marks our fourth #1 score up to now 5 years. And in the ones 5 years by myself, Robbins Geller recovered $8.4 billion for traders – $3.4 billion greater than some other regulation company. With 200 attorneys in 10 places of work, Robbins Geller is among the greatest plaintiffs’ corporations on the planet, and the Company’s lawyers have got lots of the greatest securities category motion recoveries in historical past, together with the most important ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please discuss with the next web page for more info:
https://www.rgrdlaw.com/services-litigation-securities-fraud.html
Previous effects don’t ensure long run results. Products and services could also be carried out by way of lawyers in any of our places of work.
